Afam A Okoye
Overview
Explore the profile of Afam A Okoye including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
935
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Varco-Merth B, Chaunzwa M, Duell D, Marenco A, Goodwin W, Dannay R, et al.
PLoS Pathog
. 2024 Aug;
20(8):e1012496.
PMID: 39173097
Persistence of the rebound-competent viral reservoir (RCVR) within the CD4+ T cell compartment of people living with HIV remains a major barrier to HIV cure. Here, we determined the effects...
2.
Keele B, Okoye A, Fennessey C, Varco-Merth B, Immonen T, Kose E, et al.
PLoS Pathog
. 2024 Apr;
20(4):e1012135.
PMID: 38593120
The rebound competent viral reservoir (RCVR)-virus that persists during antiretroviral treatment (ART) and can reignite systemic infection when treatment is stopped-is the primary barrier to eradicating HIV. We used time...
3.
Eichholz K, Fukazawa Y, Peterson C, Haeseleer F, Medina M, Hoffmeister S, et al.
J Clin Invest
. 2024 Apr;
134(7).
PMID: 38557496
Programmed cell death protein 1 (PD-1) is an immune checkpoint marker commonly expressed on memory T cells and enriched in latently HIV-infected CD4+ T cells. We engineered an anti-PD-1 chimeric...
4.
Pinkevych M, Docken S, Okoye A, Fennessey C, Del Prete G, Pino M, et al.
PLoS Pathog
. 2023 Oct;
19(10):e1011660.
PMID: 37801446
One approach to 'functional cure' of HIV infection is to induce durable control of HIV replication after the interruption of antiretroviral therapy (ART). However, the major factors that determine the...
5.
Lavinder T, Fachko D, Stanton J, Varco-Merth B, Smedley J, Okoye A, et al.
Comp Med
. 2022 Sep;
72(5):287-297.
PMID: 36162961
HIV-infected people develop reproducible disruptions in their gastrointestinal microbiota. Despite the suppression of HIV viremia via long-term antiretroviral therapy (ART), alterations still occur in gut microbial diversity and the commensal...
6.
Varco-Merth B, Brantley W, Marenco A, Duell D, Fachko D, Richardson B, et al.
J Clin Invest
. 2022 Mar;
132(10).
PMID: 35316218
Proliferation of latently infected CD4+ T cells with replication-competent proviruses is an important mechanism contributing to HIV persistence during antiretroviral therapy (ART). One approach to targeting this latent cell expansion...
7.
Okoye A, Fromentin R, Takata H, Brehm J, Fukazawa Y, Randall B, et al.
PLoS Pathog
. 2022 Jan;
18(1):e1010245.
PMID: 35041707
Activation of the NF-κB signaling pathway by Protein Kinase C (PKC) agonists is a potent mechanism for human immunodeficiency virus (HIV) latency disruption in vitro. However, significant toxicity risks and...
8.
Haeseleer F, Fukazawa Y, Park H, Varco-Merth B, Rust B, Smedley J, et al.
Mol Ther Methods Clin Dev
. 2021 Sep;
22:304-319.
PMID: 34485613
Chimeric antigen receptor (CAR) T cell therapies are being investigated as potential HIV cures and designed to target HIV reservoirs. Monoclonal antibodies (mAbs) targeting the simian immunodeficiency virus (SIV) envelope...
9.
CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification
Okoye A, Duell D, Fukazawa Y, Varco-Merth B, Marenco A, Behrens H, et al.
J Clin Invest
. 2021 Feb;
131(8).
PMID: 33630764
To define the contribution of CD8+ T cell responses to control of SIV reactivation during and following antiretroviral therapy (ART), we determined the effect of long-term CD8+ T cell depletion...
10.
Gramatica A, Schwarzer R, Brantley W, Varco-Merth B, Sperber H, Hull P, et al.
J Virol
. 2021 Feb;
95(8).
PMID: 33536176
An ability to activate latent HIV-1 expression could benefit many HIV cure strategies, but the first generation of latency reversing agents (LRAs) has proven disappointing. We evaluated AKT/mTOR activators as...